Noble Financial Remains a Buy on Unicycive Therapeutics (UNCY)

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $1.09.

LeBoyer covers the Healthcare sector, focusing on stocks such as Ocugen, GeoVax Labs, and PDS Biotechnology. According to TipRanks, LeBoyer has an average return of -7.8% and a 26.67% success rate on recommended stocks.

Unicycive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.88, a 439.45% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $9.00 price target.

Based on Unicycive Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $7.8 million. In comparison, last year the company had a GAAP net loss of $5.33 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Unicycive Therapeutics (UNCY) Company Description:

Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive’s other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.